MCRIP1: A Potential Drug Target and Biomarker (G348262)
MCRIP1: A Potential Drug Target and Biomarker
MCRIP1, a gene with sequence similarity 195, member B, has been identified as a potential drug target and biomarker for various diseases. MCRIP1 is a non-coding RNA molecule that has been shown to play a critical role in the regulation of cellular processes, including cell adhesion, migration, and invasion. The identification of MCRIP1 as a potential drug target and biomarker has significant implications for the development of new treatments for various diseases.
The MCRIP1 gene is located on chromosome 6p and has a length of 211 nucleotides. It is characterized by a highly conserved sequence that includes a unique intron-exon structure, a conserved core region, and a variable exon region. The variable exon region is the most variable part of the MCRIP1 gene and is responsible for the diversity of MCRIP1 expression among different cell types and tissues.
MCRIP1 is a key regulator of cell-cell adhesion, which is a critical process that ensures the integrity and survival of tissues and organs. Adhesion helps to maintain the structure and function of tissues and is involved in various physiological processes, including embryonic development, tissue repair, and cancer progression. MCRIP1 is known to play a critical role in the regulation of cell-cell adhesion by controlling the activity of several transcription factors, including E-cadherin, N-cadherin, and vimentin.
MCRIP1 is also involved in the regulation of cell migration and invasion, which are critical processes that help cells to navigate through the body and promote tissue growth and repair. MCRIP1 has been shown to play a critical role in the regulation of cell migration by controlling the activity of several transcription factors, including PDGF-尾, TGF-β, and NF-kappa-B. It is also involved in the regulation of cell invasion by controlling the activity of several transcription factors, including alpha-lactate dehydrogenase (ALDH1L1) and N-cadherin.
MCRIP1 is also a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. The identification of MCRIP1 as a potential drug target and biomarker has significant implications for the development of new treatments for these diseases.
MCRIP1 has been shown to be highly expressed in various tissues and cells, including brain, spinal cord, and pancreatic cancer. It is also shown to be involved in the regulation of cellular processes that are critical for cancer progression, including cell proliferation, angiogenesis, and metastasis. MCRIP1 has been shown to play a critical role in the regulation of cell proliferation by controlling the activity of several transcription factors, including E-cadherin, PDGF-尾, and NF-kappa-B. It is also involved in the regulation of angiogenesis by controlling the activity of several transcription factors, including vascular endothelial growth factor (VEGF) and CD133.
MCRIP1 is also involved in the regulation of metabolism and energy homeostasis. It is shown to play a critical role in the regulation of glucose metabolism by controlling the activity of several transcription factors, including Glucocorticoid receptor gene 1 (GR gene), p53 and CREB. MCRIP1 is also involved in the regulation of lipid metabolism by controlling the activity of several transcription factors, including lipid kinase 1 (LIPK1) and CDP-ChP.
MCRIP1 is also involved in the regulation of cellular processes that are critical for neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. It is shown to play
Protein Name: MAPK Regulated Corepressor Interacting Protein 1
Functions: The phosphorylation status of MCRIP1 functions as a molecular switch to regulate epithelial-mesenchymal transition. Unphosphorylated MCRIP1 binds to and inhibits the transcriptional corepressor CTBP(s). When phosphorylated by MAPK/ERK, MCRIP1 releases CTBP(s) resulting in transcriptional silencing of the E-cadherin gene and induction of epithelial-mesenchymal transition (PubMed:25728771)
The "MCRIP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MCRIP1 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MCRIP2 | MCRS1 | MCTP1 | MCTP2 | MCTS1 | MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6 | MED7 | MED8 | MED9 | MEDAG | Mediator Complex | Mediator of RNA Polymerase II Transcription | MEF2A | MEF2B | MEF2C | MEF2C-AS1 | MEF2C-AS2 | MEF2D | MEFV | MEG3 | MEG8 | MEG9 | MEGF10 | MEGF11 | MEGF6 | MEGF8 | MEGF9 | MEI1 | MEI4 | MEIG1 | MEIKIN | MEIOB | MEIOC | MEIOSIN | MEIS1 | MEIS1-AS2 | MEIS1-AS3 | MEIS2 | MEIS3
